1. Home
  2. EARN vs DBVT Comparison

EARN vs DBVT Comparison

Compare EARN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • DBVT
  • Stock Information
  • Founded
  • EARN 2012
  • DBVT 2002
  • Country
  • EARN United States
  • DBVT France
  • Employees
  • EARN N/A
  • DBVT N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EARN Real Estate
  • DBVT Health Care
  • Exchange
  • EARN Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • EARN 213.3M
  • DBVT 250.5M
  • IPO Year
  • EARN 2013
  • DBVT N/A
  • Fundamental
  • Price
  • EARN $5.92
  • DBVT $10.80
  • Analyst Decision
  • EARN Buy
  • DBVT Buy
  • Analyst Count
  • EARN 2
  • DBVT 4
  • Target Price
  • EARN $6.00
  • DBVT $14.81
  • AVG Volume (30 Days)
  • EARN 230.9K
  • DBVT 26.3K
  • Earning Date
  • EARN 08-11-2025
  • DBVT 07-29-2025
  • Dividend Yield
  • EARN 16.16%
  • DBVT N/A
  • EPS Growth
  • EARN N/A
  • DBVT N/A
  • EPS
  • EARN N/A
  • DBVT N/A
  • Revenue
  • EARN $35,893,000.00
  • DBVT $3,497,000.00
  • Revenue This Year
  • EARN $3.21
  • DBVT $1,700.53
  • Revenue Next Year
  • EARN $18.63
  • DBVT $535.67
  • P/E Ratio
  • EARN N/A
  • DBVT N/A
  • Revenue Growth
  • EARN 43.30
  • DBVT N/A
  • 52 Week Low
  • EARN $4.33
  • DBVT $2.21
  • 52 Week High
  • EARN $7.20
  • DBVT $12.78
  • Technical
  • Relative Strength Index (RSI)
  • EARN 64.84
  • DBVT 58.42
  • Support Level
  • EARN $5.71
  • DBVT $10.53
  • Resistance Level
  • EARN $5.79
  • DBVT $11.33
  • Average True Range (ATR)
  • EARN 0.06
  • DBVT 0.76
  • MACD
  • EARN 0.01
  • DBVT 0.14
  • Stochastic Oscillator
  • EARN 82.14
  • DBVT 65.90

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: